🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

107 results for “Tad” Clear

  1. cetuximab + cisplatin + vinorelbine

    Merck KGaA, Darmstadt, Germany

    Non Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule completed

    1 trial

  2. favezelimab/pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Colorectal Cancer

    phase 3 mab completed

    1 trial

  3. pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer

    phase 3 mab completed

    2 trials

  4. pembrolizumab/vibostolimab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Non-Small-Cell Lung

    phase 3 mab active

    1 trial

  5. Atomoxetin STADA 40 mg Hartkapseln, GELATIN

    Pari Pharma GmbH

    Healthy subjects with no neurological or psychiatric disorders

    phase 2 small molecule active

    1 trial

  6. Belzutifan

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Renal Cell

    phase 2 small molecule active

    1 trial

  7. Budigalimab, Sorafenib STADA 200 mg Filmtabletten, Livmoniplimab, Kisplyx 4 mg hard capsules

    AbbVie Deutschland GmbH & Co. KG

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  8. Cetuximab

    Merck KGaA, Darmstadt, Germany

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  9. DOR/ISL

    Merck KGaA, Darmstadt, Germany

    HIV-1 Infection

    phase 2 small molecule completed

    1 trial

  10. Daptomycin for Injection

    Merck KGaA, Darmstadt, Germany

    Bacteremia

    phase 2 small molecule completed

    1 trial

  11. Docetaxel

    Merck KGaA, Darmstadt, Germany

    Castration-Resistant Prostatic Cancer

    phase 2 small molecule active

    1 trial

  12. Doravirine

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV) Infection

    phase 2 small molecule active

    1 trial

  13. Efinopegdutide

    Merck KGaA, Darmstadt, Germany

    Non-alcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  14. Efinopegdutide 20 mg/mL

    Merck KGaA, Darmstadt, Germany

    Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  15. Fulvestrant STADA 250 mg injekcinis tirpalas užpildytame švirkšte, Alisertib Enteric-Coated Tablets, Exemestane SanoSwiss 25 mg plėvele dengtos tabletės, Anastrozole Accord 1 mg plėvele dengtos tabletės, Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės, Tamoxifen EBEWE 20 mg tabletės

    PUMA BIOTECHNOLOGY, INC.

    Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

    phase 2 small molecule active

    1 trial

  16. Iclusig 15 mg film-coated tablets, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., Imatinib TAD 400 mg επικαλυμμένα με λεπτό υμένιο δισκία

    Cardiff Oncology

    Blood cancer

    phase 2 small molecule active

    1 trial

  17. Intismeran autogene

    Merck KGaA, Darmstadt, Germany

    Malignant Melanoma

    phase 2 mab active

    1 trial

  18. LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, Kisqali 200 mg film-coated tablets, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, LETROZOLE, INAVOLISIB, LETROZOLE, Letrozol STADA® 2,5 mg Filmtabletten

    Hoffmann-La Roche

    Early-Stage, PIK3CA-Mutated Breast Cancer (BC)

    phase 2 small molecule active

    1 trial

  19. Loratadina NORMON 10 mg Comprimidos EFG

    The George Institute

    Effect of loratadine in patients with lymphangioleiomyomatosis

    phase 2 small molecule active

    1 trial

  20. Loratadine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rhinitis, Allergic, Perennial

    phase 2 small molecule completed

    1 trial

  21. M5049 low dose

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  22. MK-1167

    Merck KGaA, Darmstadt, Germany

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  23. MK-2214

    Merck KGaA, Darmstadt, Germany

    Early Alzheimer's Disease

    phase 2 mab active

    1 trial

  24. MK-6194

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources